Sol-Gel Technologies Ltd. (SLGL)

Market Cap	24.78M
Revenue (ttm)	1.55M
Net Income (ttm)	-27.24M
Shares Out	27.86M
EPS (ttm)	-1.01
PE Ratio	n/a
Forward PE	9.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,055
Open	0.861
Previous Close	0.890
Day's Range	0.851 - 0.900
52-Week Range	0.790 - 4.050
Beta	1.32
Analysts	Strong Buy
Price Target	8.00 (+840.07%)
Earnings Date	May 10, 2024

About SLGL

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hype...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 23, 2018
• Employees: 36
• Stock Exchange: NASDAQ
• Ticker Symbol: SLGL

Financial Performance

In 2023, SLGL's revenue was $1.55 million, a decrease of -59.98% compared to the previous year's $3.88 million. Losses were -$27.24 million, 82.5% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for SLGL stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 840.07% from the latest price.

Price Target

$8.0

(840.07% upside)

Analyst Consensus: Strong Buy